Pediatric Crohn's Disease Activity Index
The Pediatric Crohn Disease Activity Index (PCDAI) was designed to allow patient stratification by disease severity and to create a score that could measure response to therapeutic interventions in pediatric patients with Crohns disease.
It was developed by examining clinical and laboratory data on 133 children and adolescents with Crohn's disease and validating this against an index of severity of illness previously developed by a group of senior pediatric gastroenterologists.
The PCDAI includes
PCDAI scores have been validated to accurately reflect disease activity as assessed by physician global assessment.
A PCDAI score of ≥30 has acceptable sensitivity and specificity to indicate disease of moderate/severe activity. A PCDAI decrease of 12.5 points or greater following therapeutic intervention accurately reflects a clinically significant response.
The PCDAI is felt to be useful for assessing disease activity and response to therapeutics in trials studying Crohns disease in children
Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT, et al.
Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, Kugathasan S, Pfefferkorn M, Tolia V, Evans J, Treem W, Wyllie R, Rothbaum R, del Rosario J, Katz A, Mezoff A, Oliva-Hemker M, Lerer T, Griffiths A.
The Pediatric Crohn Disease Activity Index (PCDAI) was designed to allow patient stratification by disease severity and to create a score that could measure response to therapeutic interventions in pediatric patients with Crohns disease.
It was developed by examining clinical and laboratory data on 133 children and adolescents with Crohn's disease and validating this against an index of severity of illness previously developed by a group of senior pediatric gastroenterologists.
The PCDAI includes
PCDAI scores have been validated to accurately reflect disease activity as assessed by physician global assessment.
A PCDAI score of ≥30 has acceptable sensitivity and specificity to indicate disease of moderate/severe activity. A PCDAI decrease of 12.5 points or greater following therapeutic intervention accurately reflects a clinically significant response.
The PCDAI is felt to be useful for assessing disease activity and response to therapeutics in trials studying Crohns disease in children
Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT, et al.
Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, Kugathasan S, Pfefferkorn M, Tolia V, Evans J, Treem W, Wyllie R, Rothbaum R, del Rosario J, Katz A, Mezoff A, Oliva-Hemker M, Lerer T, Griffiths A.
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.
